Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VTYX |
---|---|---|
09:32 ET | 59897 | 2.2787 |
09:34 ET | 31057 | 2.27 |
09:36 ET | 3400 | 2.26 |
09:38 ET | 2887 | 2.2787 |
09:39 ET | 28616 | 2.25 |
09:41 ET | 1300 | 2.2492 |
09:43 ET | 675 | 2.2492 |
09:45 ET | 14320 | 2.255 |
09:48 ET | 9460 | 2.275 |
09:50 ET | 3245 | 2.285 |
09:52 ET | 4169 | 2.3 |
09:54 ET | 5195 | 2.3 |
09:56 ET | 345 | 2.3 |
09:57 ET | 9500 | 2.3 |
09:59 ET | 732 | 2.315 |
10:01 ET | 8300 | 2.315 |
10:03 ET | 3099 | 2.3292 |
10:06 ET | 300 | 2.325 |
10:08 ET | 1000 | 2.335 |
10:10 ET | 14014 | 2.315 |
10:12 ET | 7932 | 2.315 |
10:15 ET | 2931 | 2.3008 |
10:17 ET | 3410 | 2.2988 |
10:19 ET | 1040 | 2.295 |
10:21 ET | 6011 | 2.31 |
10:24 ET | 4230 | 2.29 |
10:26 ET | 662 | 2.29 |
10:28 ET | 100 | 2.295 |
10:30 ET | 400 | 2.29 |
10:32 ET | 600 | 2.281 |
10:33 ET | 591 | 2.285 |
10:35 ET | 1384 | 2.295 |
10:37 ET | 900 | 2.3 |
10:39 ET | 200 | 2.3 |
10:42 ET | 9737 | 2.29 |
10:44 ET | 7971 | 2.2792 |
10:46 ET | 1747 | 2.29 |
10:48 ET | 300 | 2.29 |
10:50 ET | 1100 | 2.285 |
10:51 ET | 2780 | 2.2791 |
10:53 ET | 1700 | 2.275 |
10:55 ET | 1400 | 2.275 |
10:57 ET | 5625 | 2.27 |
11:00 ET | 600 | 2.26 |
11:02 ET | 3162 | 2.26 |
11:04 ET | 1776 | 2.265 |
11:06 ET | 3600 | 2.275 |
11:08 ET | 330 | 2.28 |
11:09 ET | 400 | 2.275 |
11:11 ET | 6253 | 2.26 |
11:13 ET | 1871 | 2.2699 |
11:15 ET | 1263 | 2.275 |
11:20 ET | 3300 | 2.2689 |
11:22 ET | 3000 | 2.265 |
11:26 ET | 3441 | 2.27 |
11:27 ET | 2600 | 2.265 |
11:29 ET | 500 | 2.26 |
11:31 ET | 1843 | 2.26 |
11:33 ET | 638 | 2.2507 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Ventyx Biosciences Inc | 161.8M | -0.8x | --- |
Tenaya Therapeutics Inc | 157.8M | -1.3x | --- |
Context Therapeutics Inc | 156.7M | -1.9x | --- |
Acumen Pharmaceuticals Inc | 156.2M | -2.2x | --- |
Achieve Life Sciences Inc | 155.6M | -4.3x | --- |
Actuate Therapeutics Inc | 153.1M | -4.5x | --- |
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $161.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.79 |
Book Value | $4.12 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.